$14.50
Today
as of Aug 7, 16:45 ET
Last 30 days
Recent Press Releases & News
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
Overview
52-week range
—
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Earnings trends
Implied volatility — last 90 days
No IV snapshots yet for AGMB.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.